A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer (Q39015140)

8 September 2017

title

A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer (English)

1 reference

8 September 2017

main subject

phase I clinical trial

0 references

author

Manuel Hidalgo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25902900%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Antonio Calles

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25902900%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Irene Braña

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25902900%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Pedro P López-Casas

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25902900%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Emiliano Calvo

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25902900%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Analia Azaro

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25902900%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Jordi Rodon

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25902900%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Manuel Munoz

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25902900%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Paul Westwood

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25902900%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Joel Miller

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25902900%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Brian A Moser

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25902900%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Ute Ohnmacht

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25902900%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

William Bumgardner

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25902900%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Karim A Benhadji

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25902900%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

publication date

24 April 2015

1 reference

Investigational New Drugs

8 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25902900%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25902900%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25902900%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

710-719

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25902900%20AND%20SRC:MED&resulttype=core&format=json

Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).

10 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

Updates of mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

Exploiting the PI3K/AKT pathway for cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

Targeting the PI3K signaling pathway in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

Role for Akt3/protein kinase Bgamma in attainment of normal brain size

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

The Akt kinases: isoform specificity in metabolism and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

Revised response criteria for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

The APL paradigm and the "co-clinical trial" project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

Antitumor activity of ridaforolimus and potential cell-cycle determinants of sensitivity in sarcoma and endometrial cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and ro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

Biomarkers of response to Akt inhibitor MK-2206 in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0241-7

An in vivo platform for translational drug development in pancreatic cancer

21 January 2018

1 reference

12 December 2020

Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.

1 reference

12 December 2020

AKT and cancer--is it all mTOR?

1 reference

12 December 2020

mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer

1 reference

12 December 2020

Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition

1 reference

12 December 2020

Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling

1 reference

12 December 2020